{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:17:41Z","timestamp":1787242661442,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.retram.2021.103300","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T01:29:26Z","timestamp":1625534966000},"page":"103300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Heparin beyond anti-coagulation"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4060-6050","authenticated-orcid":false,"given":"Daohong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2021.103300_bib0001","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/jth.13555","article-title":"A century for heparin: past, present and future","volume":"14","author":"Hemker","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.retram.2021.103300_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-23056-1_1","article-title":"History of heparin","volume":"217","author":"Barrowcliffe","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.retram.2021.103300_bib0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ph9030038","article-title":"Heparin: past, present, and future","volume":"9","author":"Oduah","year":"2016","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.retram.2021.103300_bib0004","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/molecules22050749","article-title":"New applications of heparin and other glycosaminoglycans","volume":"22","author":"Lima","year":"2017","journal-title":"Molrcules"},{"key":"10.1016\/j.retram.2021.103300_bib0005","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.retram.2021.103300_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.trsl.2020.05.007","article-title":"Innovative highlights of clinical drug trial design","volume":"224","author":"Chen","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.retram.2021.103300_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12882-017-0596-4","article-title":"Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis","volume":"18","author":"Lazrak","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.retram.2021.103300_bib0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2016.12.002","article-title":"Heparin coatings for improving blood compatibility of medical devices","volume":"112","author":"Biran","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"issue":"Suppl 1","key":"10.1016\/j.retram.2021.103300_bib0009","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0167-5273(16)12004-2","article-title":"Old and new applications of non-anticoagulant heparin","volume":"212","author":"Cassinelli","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.retram.2021.103300_bib0010","first-page":"1232","article-title":"Low molecular weight heparin use in unexplained recurrent miscarriage","volume":"30","author":"Yuksel","year":"2014","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.retram.2021.103300_bib0011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/IJWH.S193293","article-title":"Timing of initiation of low-molecular-weight heparin administration in pregnant women with antiphospholipid syndrome: a randomized clinical trial of efficacy and safety","volume":"11","author":"Eid","year":"2019","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.retram.2021.103300_bib0012","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5603\/GP.a2017.0049","article-title":"The impact of low molecular weight heparin on obstetric outcomes among unexplained recurrent miscarriages complicated with methylenetetrahydrofolate reductase gene polymorphism","volume":"88","author":"Cetin","year":"2017","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.retram.2021.103300_bib0013","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/humupd\/dmt032","article-title":"Adjunct low-molecular-weight heparin to improve live birth rate after recurrent implantation failure: a systematic review and meta-analysis","volume":"19","author":"Potdar","year":"2013","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.retram.2021.103300_bib0014","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/j.1538-7836.2011.04535.x","article-title":"Efficacy of low molecular weight heparin in patients undergoing in vitro fertilization or intracytoplasmic sperm injection","volume":"9","author":"Dentali","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.retram.2021.103300_bib0015","article-title":"Anti-inflammatory effects of heparin and its derivatives: a systematic review","volume":"2015","author":"Mousavi","year":"2015","journal-title":"Adv Pharmacol Sci"},{"key":"10.1016\/j.retram.2021.103300_bib0016","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3892\/etm.2013.1001","article-title":"Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage","volume":"5","author":"Shi","year":"2013","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.retram.2021.103300_bib0017","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3892\/etm.2013.919","article-title":"Prothrombotic state in senile patients with acute exacerbations of chronic obstructive pulmonary disease combined with respiratory failure","volume":"5","author":"Song","year":"2013","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.retram.2021.103300_bib0018","article-title":"Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics","volume":"10","author":"Shastri","year":"2015","journal-title":"PLoS ONE"},{"issue":"Suppl 2","key":"10.1016\/j.retram.2021.103300_bib0019","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.2337\/dc08-s251","article-title":"Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin","volume":"31","author":"Lewis","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.retram.2021.103300_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2215\/CJN.02400706","article-title":"Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system","volume":"2","author":"Benck","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.retram.2021.103300_bib0021","doi-asserted-by":"crossref","first-page":"8613","DOI":"10.3892\/mmr.2017.7697","article-title":"Low molecular weight heparin may benefit nephrotic remission in steroidsensitive nephrotic syndrome via inhibiting elastase","volume":"16","author":"Zhai","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.retram.2021.103300_bib0022","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4137\/CCRep.S40607","article-title":"Therapeutic Dilemmas regarding anticoagulation: an experience in a patient with nephrotic syndrome, pulmonary embolism, and traumatic brain injury","volume":"9","author":"Akimoto","year":"2016","journal-title":"Clin Med Insights Case Rep"},{"key":"10.1016\/j.retram.2021.103300_bib0023","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-015-1880-5","article-title":"A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency","volume":"71","author":"Atiq","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.retram.2021.103300_bib0024","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.14885","article-title":"The role of heparin in sepsis: much more than just an anticoagulant","volume":"179","author":"Li","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.retram.2021.103300_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13054-016-1415-1","article-title":"Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan","volume":"20","author":"Yamakawa","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.retram.2021.103300_bib0026","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s13054-014-0563-4","article-title":"Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.retram.2021.103300_bib0027","doi-asserted-by":"crossref","first-page":"25984","DOI":"10.1038\/srep25984","article-title":"Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials","volume":"6","author":"Fan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.retram.2021.103300_bib0028","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/jcph.1100","article-title":"Dual targeting autoimmunity and cancer: from biology to medicine","volume":"558","author":"Chen","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.retram.2021.103300_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with\u2002COVID-19 in Wuhan, China: a retrospective cohort study","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.retram.2021.103300_bib0030","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection\u2013a review of immune changes in patients with viral pneumonia","author":"Lin","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.retram.2021.103300_bib0031","doi-asserted-by":"crossref","first-page":"E354","DOI":"10.3390\/ijms18020354","article-title":"The interplay between inflammation, coagulation and endothelial injury in the early phase of acute pancreatitis: clinical implications","volume":"18","author":"Dumnicka","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.retram.2021.103300_bib0032","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5152\/tjg.2018.18583","article-title":"Low molecular weight heparin treatment of acute moderate and severe pancreatitis: a randomized, controlled,open-label study","volume":"30","author":"Tozlu","year":"2019","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.retram.2021.103300_bib0033","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/1751-2980.12815","article-title":"The efficacy of low molecular weight heparin in severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Qiu","year":"2019","journal-title":"J Dig Dis"},{"key":"10.1016\/j.retram.2021.103300_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-008550","article-title":"Acute pancreatitis owing to very high triglyceride levels treated with insulin and heparin infusion","volume":"2013","author":"Aryal","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.retram.2021.103300_bib0035","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0018578717725168","article-title":"Treatment of hypertriglyceridemia-induced acute pancreatitis with insulin, heparin, and gemfibrozil: a case series","volume":"52","author":"Hammond","year":"2017","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.retram.2021.103300_bib0036","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3747\/co.21.1864","article-title":"Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management","volume":"21","author":"Donnellan","year":"2014","journal-title":"Curr Oncol"},{"key":"10.1016\/j.retram.2021.103300_bib0037","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and venous thromboembolic disease: a review","volume":"22","author":"Donnellan","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.retram.2021.103300_bib0038","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/0008-5472.CAN-13-2817","article-title":"Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle","volume":"74","author":"Chen","year":"2014","journal-title":"Cancer Res"},{"issue":"Supplement","key":"10.1016\/j.retram.2021.103300_bib0039","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.4103\/0973-1482.176174","article-title":"Low molecular weight heparin in treating patients with lung cancer received chemotherapy: a meta-analysis","volume":"14","author":"Liu","year":"2018","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"10.1016\/j.retram.2021.103300_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030566","article-title":"Potential mechanisms of cancer-related hypercoagulability","volume":"12","author":"Nasser","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2021.103300_bib0041","doi-asserted-by":"crossref","first-page":"e10772","DOI":"10.1097\/MD.0000000000010772","article-title":"Pembrolizumab-induced acute thrombosis: a case report","volume":"97","author":"Kunimasa","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"21","key":"10.1016\/j.retram.2021.103300_bib0042","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.3346\/jkms.2019.34.e160","article-title":"Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer","volume":"34","author":"Lee","year":"2019","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.retram.2021.103300_bib0043","article-title":"How I treat cancer-associated thrombosis","volume":"5","author":"Moik","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.retram.2021.103300_bib0044","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18673.1","article-title":"Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges","volume":"8","author":"Farge","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.retram.2021.103300_bib0045","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s40880-015-0047-1","article-title":"Targeted therapy: resistance and re-sensitization","volume":"34","author":"Chen","year":"2015","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.retram.2021.103300_bib0046","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000188","article-title":"Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options","volume":"2","author":"Ay","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.retram.2021.103300_bib0047","first-page":"596","article-title":"Effect of low molecular weight heparin (enoxaparin) on congenital cataract surgery","volume":"5","author":"Caca","year":"2012","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.retram.2021.103300_bib0048","first-page":"e3157","article-title":"Role of heparin irrigation in the management of superficial burns with special reference to pain relief and wound healing: a pilot study","volume":"10","author":"Vijayakumar","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.retram.2021.103300_bib0049","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0022-5223(95)70117-6","article-title":"Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits","volume":"110","author":"Jansen","year":"1995","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1016\/j.retram.2021.103300_bib0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00002480-200005000-00015","article-title":"Prevalence and persistence of heparin\/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices","volume":"46","author":"Koster","year":"2000","journal-title":"ASAIO J"},{"key":"10.1016\/j.retram.2021.103300_bib0051","first-page":"1","article-title":"Heparin 2.0: a new approach to the infection crisis","author":"Seffer","year":"2020","journal-title":"Blood Purif"},{"key":"10.1016\/j.retram.2021.103300_bib0052","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4103\/1673-5374.274341","article-title":"Inhibition of BACE1, the \u03b2-secretase implicated in\u2002Alzheimer's\u2002disease, by a chondroitin sulfate extract from Sardina pilchardus","volume":"15","author":"Mycroft-West","year":"2020","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.retram.2021.103300_bib0053","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/978-3-030-34521-1_20","article-title":"Non-anticoagulant heparins as heparanase inhibitors","volume":"1221","author":"Cassinelli","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.retram.2021.103300_bib0054","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/bloodadvances.2017013391","article-title":"Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia","volume":"2","author":"Kovacsovics","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2021.103300_bib0055","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.3324\/haematol.2017.182865","article-title":"Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy","volume":"103","author":"Galli","year":"2018","journal-title":"Haematologica"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862100026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862100026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:39:31Z","timestamp":1762821571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245231862100026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S245231862100026X"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2021.103300","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heparin beyond anti-coagulation","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2021.103300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103300"}}